These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22871196)

  • 21. Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.
    Scott SA; Patel M; Martis S; Lubitz SA; van der Zee S; Yoo C; Edelmann L; Halperin JL; Desnick RJ
    Pharmacogenomics; 2012 Feb; 13(3):297-307. PubMed ID: 22188360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
    Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing.
    Chan SL; Suo C; Chia KS; Teo YY
    Pharmacogenomics; 2012 Aug; 13(11):1247-56. PubMed ID: 22920395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians.
    Schelleman H; Chen Z; Kealey C; Whitehead AS; Christie J; Price M; Brensinger CM; Newcomb CW; Thorn CF; Samaha FF; Kimmel SE
    Clin Pharmacol Ther; 2007 May; 81(5):742-7. PubMed ID: 17329985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic and clinical predictors of warfarin dose requirements in African Americans.
    Cavallari LH; Langaee TY; Momary KM; Shapiro NL; Nutescu EA; Coty WA; Viana MA; Patel SR; Johnson JA
    Clin Pharmacol Ther; 2010 Apr; 87(4):459-64. PubMed ID: 20072124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
    Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
    Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Possible application of pharmacogenomics to warfarin therapy].
    Murata M
    Rinsho Byori; 2011 Jun; 59(6):594-7. PubMed ID: 21815482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Race influences warfarin dose changes associated with genetic factors.
    Limdi NA; Brown TM; Yan Q; Thigpen JL; Shendre A; Liu N; Hill CE; Arnett DK; Beasley TM
    Blood; 2015 Jul; 126(4):539-45. PubMed ID: 26024874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.
    Ohno M; Yamamoto A; Ono A; Miura G; Funamoto M; Takemoto Y; Otsu K; Kouno Y; Tanabe T; Masunaga Y; Nonen S; Fujio Y; Azuma J
    Eur J Clin Pharmacol; 2009 Nov; 65(11):1097-103. PubMed ID: 19582440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic testing for warfarin dosing? Not yet ready for prime time.
    Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
    Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
    [No Abstract]   [Full Text] [Related]  

  • 32. A randomized controlled trial of genotype-based Coumadin initiation.
    Burmester JK; Berg RL; Yale SH; Rottscheit CM; Glurich IE; Schmelzer JR; Caldwell MD
    Genet Med; 2011 Jun; 13(6):509-18. PubMed ID: 21423021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients.
    Choi JR; Kim JO; Kang DR; Yoon SA; Shin JY; Zhang X; Roh MO; Hong HJ; Wang YP; Jo KH; Lee KS; Yun HJ; Oh YS; Yoo KD; Jeon HG; Lee YS; Kang TS; Park HJ; Chung MW; Kang JH
    J Hum Genet; 2011 Apr; 56(4):290-5. PubMed ID: 21326313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.
    Ma C; Zhang Y; Xu Q; Yang J; Zhang Y; Gao L; Xu B; Wang H; Li Y; Lu C; Yin T
    Int J Hematol; 2012 Dec; 96(6):719-28. PubMed ID: 23104259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
    Stehle S; Kirchheiner J; Lazar A; Fuhr U
    Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Warfarin pharmacogenetics: ready for clinical utility?
    Baudhuin LM
    Clin Lab Sci; 2009; 22(3):151-5. PubMed ID: 19827409
    [No Abstract]   [Full Text] [Related]  

  • 37. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
    Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
    J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic pharmacogenetic models in anticoagulation therapy.
    Bon Homme M; Reynolds KK; Valdes R; Linder MW
    Clin Lab Med; 2008 Dec; 28(4):539-52. PubMed ID: 19059061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans.
    Kimmel SE; Christie J; Kealey C; Chen Z; Price M; Thorn CF; Brensinger CM; Newcomb CW; Whitehead AS
    Pharmacogenomics J; 2008 Feb; 8(1):53-60. PubMed ID: 17325732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.